Clinical trials: insulin glargine
Diabetes Mellitus, Type 1
Efficacy Study on the Control of Blood Glucose Concentration in Type 1 Diabetic Patients
·Main objective: To compare the variability of fasting capillary blood glucose concentration, observed with insulin glargine combined with insulin glulisine and with insulin detemir combined with insulin glulisine, in type 1…
- Trial name
- VARIABILITE (NCT00271284)
- Testing
- insulin glulisine / insulin glargine, insulin glulisin / insulin detemir
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
Comparison of Efficacy and Safety of Insulin Detemir and Insulin Glargine in Patients With Type 1 Diabetes
The trial is conducted in Europe and Africa. The aim of the trial is to compare the use of insulin detemir twice daily combined with mealtime insulin aspart against that of insulin glargine once daily combined with mealtime…
- Trial name
- NCT00312104
- Testing
- insulin detemir, insulin glargine, insulin aspart
- Where
- 46 sites in Austria, Germany and 1 more
- Volunteers
- 325 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
It has been shown that individuals with type 2 diabetes have higher blood sugar throughout the night than individuals without type 2 diabetes.
- Trial name
- NCT05098470
- Testing
- Metformin, Insulin Glargine, Dorzagliatin
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of Alabama at Birmingham
Glucose, Blood
Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients
Insulin infusions are commonly used in hospitalized diabetics to control blood sugar, and they are effective. However, insulin infusions require the use of limited resources.
- Trial name
- IICE (NCT00645827)
- Testing
- IICE Dosing, Healthcare Provider dosing
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Emory University
Diabetes Mellitus, Type 2 Treated With Insulin
Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue
The association of insulin degludec with liraglutide in the same device (IDegLira) is a potent but at the same time safe drug that reduces the risk of hypoglycemia when compared to a basal or basal-bolus insulin schedule.
- Trial name
- NCT05767255
- Testing
- insulin degludec + liraglutide, Insulin Glargine - Insulin Aspart
- Where
- Colombia
- Volunteers
- 66 people
- Sponsor
- Hospital Universitario San Ignacio
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy on blood glucose control in type 2 diabetes.
- Trial name
- EUROMIX (NCT00619697)
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- 54 sites in Austria, Czechia and 5 more
- Volunteers
- 260 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2 Diabetes Mellitus
The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic Patients
In type 2 diabetic patients, tight blood glucose control often requires both fasting and post-prandial glucose control separately.
- Trial name
- NCT00437918
- Testing
- nateglinide, acarbose
- Where
- 2 sites in South Korea
- Volunteers
- 85 people
- Sponsor
- Inje University
Type 2 Diabetes (T2D)
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
This study is an open-label, 1:1 randomized, active-controlled, 2-arm, 20-week treatment duration, parallel-group, multicenter, phase IV study to evaluate the effect of iGlarLixi versus Gla-100 on glycemic control measured as TIR…
- Trial name
- China Soli-CGM (NCT06671587)
- Testing
- iGlarLixi (insulin glargine/lixisenatide), Gla-100 (insulin glargine)
- Where
- China
- Volunteers
- 678 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin…
- Trial name
- INITIATE (NCT00598793)
- Testing
- biphasic insulin aspart, insulin glargine, metformin
- Where
- 27 sites in United States
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
This study is a prospective, open-label, multicenter, parallel-group, positive-controlled, and pragmatic randomized clinical trial (pRCT).
- Trial name
- NCT07307235
- Testing
- iGlarLixi (insulin glargine/lixisenatide), standard of care (basal insulin or premixed insulin, excluding any GLP-1 receptor agonist-containing drugs)
- Where
- 24 sites in China
- Volunteers
- 1,316 people
- Sponsor
- Shanghai Zhongshan Hospital
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
- Trial name
- NCT00838916
- Testing
- albiglutide, insulin glargine
- Where
- 337 sites in United States, Russia and 2 more
- Volunteers
- 779 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes (T1D)
Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali
This study aimed to evaluate the impact on blood glucose control and quality of life in children and youth with type 1 diabetes in Mali by switching the insulin regimen from human insulin via needle and syringe, to long-acting…
- Trial name
- NCT06624943
- Testing
- biosimilar insulin glargine
- Where
- Mali
- Volunteers
- 260 people
- Sponsor
- Life for a Child Program, Diabetes Australia
Diabetes Mellitus, Type 2
Insulin Glargine During and After the Period of Fasting in Ramadan
Primary Objectives : To compare the number of hypoglycaemic events (severe, symptomatic, asymptomatic, nocturnal) in patients with type 2 diabetes treated with insulin glargine (Lantus®) and glimepiride (Amaryl®), before, during…
- Trial name
- NCT00258804
- Testing
- Insulin glargine
- Volunteers
- 450 people
- Sponsor
- Sanofi
Diabetes Mellitus, Non-Insulin-Dependent
The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)
The primary objectives of the ORIGIN study were: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired…
- Trial name
- ORIGIN (NCT00069784)
- Testing
- insulin glargine (HOE901), omega-3 polyunsaturated fatty acids (PUFA), reusable pen device for insulin injection
- Where
- 40 sites in United States, Argentina and 38 more
- Volunteers
- 12,537 people
- Sponsor
- Sanofi
Type2diabetes, Coronary Artery Disease
Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes
The purpose of the trial is to examine whether treatment with dapagliflozin plus insulin as compared with insulin alone (basal-bolus insulin) will result in similar blood glucose control and similar rate of complications in…
- Trial name
- NCT05457933
- Testing
- Dapagliflozin, Glargine
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Medanta, The Medicity, India
Diabetes Mellitus, Type 2
Comparison of Two Approaches to Insulin Therapy in Patients With Type 2 Diabetes (IOOX)
A study of patients with type 2 diabetes and inadequate glycemic control on two or more oral antihyperglycemic agents comparing adding insulin lispro mid mixture to the oral antihyperglycemic agents to adding insulin glargine to…
- Trial name
- IOOX (NCT00377858)
- Testing
- Insulin lispro mid mixture (MM), Insulin glargine
- Where
- 25 sites in Australia, Canada and 5 more
- Volunteers
- 484 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Liraglutide Hospital Discharge Trial
High blood glucose levels in hospitalized patients with diabetes are associated with increased risk of medical complications and death.
- Trial name
- NCT01919489
- Testing
- Liraglutide + OADs, Glargine + OADs
- Where
- 5 sites in United States
- Volunteers
- 273 people
- Sponsor
- Emory University
Type II Diabetes, Nonalcoholic Fatty Liver
Fatty Liver Study in Patients With Type II Diabetes
The primary objective of this trial is to measure changes in hepatic lipid content using three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with…
- Trial name
- NCT02365233
- Testing
- DPP4 inhibitor, Pioglitazone, Lantus insulin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Diabetes Mellitus, Type 2, Patient Discharge
Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin
Diabetes is present in 25% of hospitalized patients; yet effective hospital discharge programs for patients with diabetes are understudied.
- Conditions
- Diabetes Mellitus, Type 2, Patient Discharge, Blood Glucose, Low, Blood Glucose, High
- Trial name
- NCT03455985
- Testing
- Discharge Order Set (DOS), Enhanced Standard Care (ESC)
- Where
- United States
- Volunteers
- 158 people
- Sponsor
- Ohio State University
Diabetes
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
This study will be conducted to compare the efficacy, safety and patient-reported outcome of once-weekly GZR4 and once-daily Insulin Glargine U100 with Non-Insulin Antidiabetic Agents in Insulin-naive Subjects with Type 2…
- Trial name
- NCT06767735
- Testing
- GZR4, Insulin Glargine U100
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Gan & Lee Pharmaceuticals.